• About us
• Contact

Advertisement

Organisation › Details

BlueRock Therapeutics LP

BlueRock Therapeutics, a wholly owned and independently operated subsidiary of Bayer AG, is a leading engineered cell therapy company with a mission to develop regenerative medicines for intractable diseases. BlueRock Therapeutics’ cell+gene platform harnesses the power of cells for new medicines across neurology, cardiology and immunology indications. BlueRock Therapeutics’ cell differentiation technology recapitulates the cell’s developmental biology to produce authentic cell therapies, which are further engineered for additional function. Utilizing these cell therapies to replace damaged or degenerated tissue brings the potential to restore or regenerate lost function. BlueRock’s culture is defined by scientific innovation, highest ethical standards and an urgency to bring transformative treatments to all who would benefit. *

 

	Start	2016-12-12 established jv
	Group	Bayer (Group)
	Industry	iPSC technology (induced pluripotent stem cell technology)
	Industry 2	CELL+GENE™ platform
	Person	Nuwaysir, Emile (Bayer 201904 CEO of BlueRock Therapeutics)
	Person 2	Ettenberg, Seth (Bayer 202003– CSO BlueRock Therapeutics before Unum Therapeutics + Novartis IBR + CuraGen)
	Region	Cambridge, MA
	Country	United States (USA)
	Street	1 Broadway
	City	02142 Cambridge, MA
		Address record changed: 2024-01-05
Basic data	Employees	n. a.
		* Document for »About Section«: BlueRock Therapeutics LP. (3/3/20). "Press Release: BlueRock Therapeutics Appoints Seth Ettenberg, Ph.D. Chief Scientific Officer". Cambridge, MA.
		Record changed: 2023-10-26

Advertisement

More documents for Bayer (Group)

• [1] ProBioGen AG. (4/30/24). "Press Release: Change in Management". Berlin....
• [2] Evotec SE. (4/30/24). "Press Release: Bayer and Evotec Collaborate to Advance Precision Cardiology". Berlin & Hamburg....
• [3] Aignostics GmbH. (3/14/24). "Press Release: Bayer and Aignostics to Collaborate on Next Generation Precision Oncology"....
• [4] BenevolentAI Ltd.. (1/24/24). "Press Release: BenevolentAI Appoints Dr. Joerg Moeller as Chief Executive Officer". London....
• [5] Bayer AG. (10/10/23). "Press Release: Bayer Invests 250 million USD in New Cell Therapy Manufacturing Facility in the U.S. [Not intended for US and UK Media]". Berlin....
• [6] Twist Bioscience Corporation. (10/5/23). "Press Release: Twist Bioscience Enters into Antibody Discovery and Licensing Option Agreement with Bayer of up to $188 Million". Hamburg & Singapore....
• [7] Bayer AG. (9/21/23). "Press Release: Bayer to Collaborate with Hologic in Breast cancer Imaging [Not intended for U.S. and UK Media]". Berlin....
• [8] Bayer AG. (8/30/23). "Press Release: Strong Commitment to Modern Crop Protection Made in Europe. Bayer to Invest EUR 220 Million in New R&D Facility at Its Monheim Site". Monheim....
• [9] Bayer AG. (8/29/23). "Press Release: Gene Editing – Pairwise and Bayer Start New Five-year Multi-million Dollar Collaboration to Further Advance Short-stature Corn". Durham, NC & Monheim....
• [10] BlueRock Therapeutics LP. (8/23/23). "Press Release: BlueRock’s Phase I Study with Bemdaneprocel in Patients with Parkinson’s Disease Meets Primary Endpoint". Wuppertal....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.